OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes
Michał Pochopień, David Z.I. Cherney, Kerstin Folkerts, et al.
The American Journal of Managed Care (2021) Vol. 27, Iss. Suppl 20, pp. S375-S382
Open Access | Times Cited: 9
Michał Pochopień, David Z.I. Cherney, Kerstin Folkerts, et al.
The American Journal of Managed Care (2021) Vol. 27, Iss. Suppl 20, pp. S375-S382
Open Access | Times Cited: 9
Showing 9 citing articles:
Cardiorenal benefits of finerenone: protecting kidney and heart
José Ramón González‐Juanatey, José Luis Górriz, Alberto Ortíz, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 502-513
Open Access | Times Cited: 32
José Ramón González‐Juanatey, José Luis Górriz, Alberto Ortíz, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 502-513
Open Access | Times Cited: 32
Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model
David Z.I. Cherney, Aleksandra Drzewiecka‐Antonik, Kerstin Folkerts, et al.
Journal of Medical Economics (2025), pp. 1-19
Open Access | Times Cited: 1
David Z.I. Cherney, Aleksandra Drzewiecka‐Antonik, Kerstin Folkerts, et al.
Journal of Medical Economics (2025), pp. 1-19
Open Access | Times Cited: 1
Role and application prospective of non-steroidal MRA in the treatment of diabetic kidney disease
Yuying Sun, Mingzhu Wang
International Urology and Nephrology (2025)
Closed Access
Yuying Sun, Mingzhu Wang
International Urology and Nephrology (2025)
Closed Access
Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China
Jian Ming, Guanqi Hong, Yingrui Xu, et al.
Advances in Therapy (2024) Vol. 41, Iss. 8, pp. 3138-3158
Closed Access | Times Cited: 3
Jian Ming, Guanqi Hong, Yingrui Xu, et al.
Advances in Therapy (2024) Vol. 41, Iss. 8, pp. 3138-3158
Closed Access | Times Cited: 3
Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
S. W. Quist, Alexander V. van Schoonhoven, Stephan J. L. Bakker, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 8
S. W. Quist, Alexander V. van Schoonhoven, Stephan J. L. Bakker, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 8
Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
Emily Ashjian, Megan M. Clarke, Kristen Pogue
American Journal of Health-System Pharmacy (2023) Vol. 80, Iss. 23, pp. 1708-1721
Open Access | Times Cited: 6
Emily Ashjian, Megan M. Clarke, Kristen Pogue
American Journal of Health-System Pharmacy (2023) Vol. 80, Iss. 23, pp. 1708-1721
Open Access | Times Cited: 6
Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States
Cailin Zheng, Jinneng Wu, Na Li, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
Cailin Zheng, Jinneng Wu, Na Li, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
Geographical variation in kidney function testing and associations with health care costs among patients with chronic kidney disease and type 2 diabetes
Keith A. Betts, Jinlin Song, Jay Elliott, et al.
The American Journal of Managed Care (2022) Vol. 28, Iss. Suppl 6, pp. S112-S119
Open Access | Times Cited: 4
Keith A. Betts, Jinlin Song, Jay Elliott, et al.
The American Journal of Managed Care (2022) Vol. 28, Iss. Suppl 6, pp. S112-S119
Open Access | Times Cited: 4
Validation of the FINE-CKD model for future health technology assessments for finerenone in patients with chronic kidney disease and type 2 diabetes
Michał Pochopień, David Z.I. Cherney, Aleksandra Drzewiecka‐Antonik, et al.
The American Journal of Managed Care (2022) Vol. 28, Iss. Suppl 6, pp. S104-S111
Open Access | Times Cited: 3
Michał Pochopień, David Z.I. Cherney, Aleksandra Drzewiecka‐Antonik, et al.
The American Journal of Managed Care (2022) Vol. 28, Iss. Suppl 6, pp. S104-S111
Open Access | Times Cited: 3
